FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.
RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a ...
Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...
Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...
Aug. 22, 2005 — The European Commission has approved adalimumab subcutaneous injection for the treatment of psoriatic arthritis and as first-line therapy for severe, active, and progressive rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results